In 2021, a greater number of global pulmonary arterial hypertension cases occurred in females vs. males, and disease prevalence reached its highest point at age 75 to 79 years, according to data ...

Cite this: Top Ten List in Pulmonary Vascular Disease - Medscape - Feb 01, 2005. Pulmonary Arterial Hypertension Guidelines Genetics and Pathophysiology of Pulmonary Vasculopathies ...

Long-term exposure to particulate matter in patients with pulmonary arterial hypertension increases risk for lung transplantation or death.

A relatively new therapy used to treat pulmonary arterial hypertension in those with mild to moderate disease was found to be effective at preventing death in those with more advanced disease.

Shares of Insmed jumped Tuesday after the biopharmaceutical firm reported positive results from a Phase 2 trial for its ...

A Phase 3 clinical trial testing the experimental daily oral treatment ralinepag in people with PAH has completed enrollment.

BMPER attenuated PI3K/AKT signaling and suppressed BMP4-driven smooth muscle activation in models of PAH. BMPER overexpression mitigated the vascular remodeling that characterizes pulmonary arterial ...

Only five days after FDA approval of Yutrepia, Liquidia announced its first commercial shipment of the therapy, making prescriptions available to patients at specialty pharmacies. “We have moved with ...

In PAH, pulmonary rehabilitation referral and participation rates are low and are significantly affected by demographic and socioeconomic factors.

those with pulmonary vascular disease, or environmental lung disease. The pulmonary rehabilitation team of doctors, dietitians, and respiratory therapists hold a variety of.

Merck’s phase 3 HYPERION study of Winrevair meets primary endpoint in recently diagnosed adults with pulmonary arterial hypertension: Rahway, New Jersey Tuesday, June 24, 2025, ...